Cite
HARVARD Citation
Wang, Z. et al. (2018). Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet. 6 (9), pp. 681-690. [Online].